TYK351: Difference between revisions
https://pedsanesthesia.net/wikiOLD032021>TYK bot Bot: Automated import of articles |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| (One intermediate revision by the same user not shown) | |||
| Line 27: | Line 27: | ||
<p style="text-align: center;">[[TYK350|<Prev Question]] --- [[TYK352|Next Question>]]</p> | <p style="text-align: center;">[[TYK350|<Prev Question]] --- [[TYK352|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
Latest revision as of 02:29, 25 September 2026
Which class of antineoplastic agents is most likely to lead to dilated cardiomyopathy?
a) Alkylating agents
b) Anthracyclines
c) Antimetabolites
d) Anti-mitotic agents
Click for Answer
Answer
Answer b. While nearly all of the antineoplastic therapies may cause lifethreatening complications when administered at high doses, of the choices offered the anthracyclines are most commonly associated with cardiomyopathy.
Notes
- This question originally printed in the Pediatric Anesthesiology Review Topics kindle book series, and appears courtesy of Naerthwyn Press, LLC.